SynthesisComplementary therapies in medicine2022
The effectiveness of high-dose intravenous vitamin C for patients with coronavirus disease 2019: A systematic review and meta-analysis.
Synthesis in Complementary therapies in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Efficacy of vitamin C in COVID-19 management: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- The effect of macronutrient and micronutrient supplements on COVID-19: an umbrella review.Journal of health, population, and nutrition · 2024Pooled it
- The Association Between Antioxidants and COVID-19 Outcomes: a Systematic Review on Observational Studies.Biological trace element research · 2023Pooled it
- High-Dose Intravenous Vitamin C in Critical Illness: A Translational Exposure-Response Framework for Biomarker-Guided Precision Therapy.Medical sciences (Basel, Switzerland) · 2026Review
- Vitamin C in Oral Lichen Planus: Pathobiological Rationale and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Ultra-Low-Dose Inhalation of Melphalan as an Additional Treatment for COVID-19-Associated Pneumonia.Journal of clinical medicine · 2025Article
- The Role of Diet and Specific Nutrients during the COVID-19 Pandemic: What Have We Learned over the Last Three Years?International journal of environmental research and public health · 2023Review
- Role of vitamins A, C, D, E in cancer prevention and therapy: therapeutic potentials and mechanisms of action.Frontiers in nutrition · 2023Review
- Current role of high dose vitamin C in sepsis management: A concise review.World journal of critical care medicine · 2022Review
- Role of high dose vitamin C in management of hospitalised COVID-19 patients: A minireview.World journal of virology · 2022Review
- Impact of high-dose vitamin C on the mortality, severity, and duration of hospital stay in COVID-19 patients: A meta-analysis.Health science reports · 2022Article
- Review
- YouTube as a source of information regarding the effect of vitamin C on coronavirus disease.Complementary therapies in medicine · 2022Article
- The Variable Nature of Vitamin C-Does It Help When Dealing with Coronavirus?Antioxidants (Basel, Switzerland) · 2022Review
- Vitamin C for COVID-19 Treatment: Have We Got Enough Evidence?Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesVitamin C has anti-inflammatory effects. This review aimed to investigate the therapeutic effect of high-dose intravenous vitamin C (HDIVC) in patients with coronavirus disease 2019 (COVID-19).
methodsThe following key phrases were searched for article inclusion: "Vitamin C OR ascorbic acid" AND "COVID-19 OR coronavirus disease 2019 OR severe acute respiratory syndrome coronavirus 2 OR SARS-CoV-2″. Articles that utilized HDIVC for the management of patients with COVID-19 were included, whereas review articles and case reports were excluded from this review. Moreover, we performed a meta-analysis to evaluate whether HDIVC can reduce the length of hospital stay and in-hospital mortality rate of patients with severe COVID-19.
resultsIn total, eight articles were included in this review, and five studies were included in the meta-analysis. The length of hospital stay was not significantly different between the HDIVC and control groups. Also, although our meta-analysis showed a tendency for HDIVC to reduce the in-hospital mortality rate in patients with severe COVID-19, the in-hospital mortality rate was not significantly different between patients treated with HDIVC and those who did not receive HDIVC.
conclusionsEvidence supporting the therapeutic use of HDICV in COVID-19 patients is lacking. Further studies are required for drawing a clear conclusion on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.